Format

Send to

Choose Destination
Biomed Pharmacother. 2019 Apr 23;115:108870. doi: 10.1016/j.biopha.2019.108870. [Epub ahead of print]

Protective effects of Rosavin on bleomycin-induced pulmonary fibrosis via suppressing fibrotic and inflammatory signaling pathways in mice.

Author information

1
Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, College of Pharmacy, Shihezi University, Shihezi, 832002, China.
2
Shenzhen Honghui Biopharmaceutical Co., Ltd. Shenzhen 518000, China; Department of Pharmacology, School of Medicine, Shenzhen University, Shenzhen, 518060, China.
3
Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, College of Pharmacy, Shihezi University, Shihezi, 832002, China. Electronic address: tcm_zk@suda.163.com.
4
Shenzhen Honghui Biopharmaceutical Co., Ltd. Shenzhen 518000, China.
5
Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, College of Pharmacy, Shihezi University, Shihezi, 832002, China; Shenzhen Honghui Biopharmaceutical Co., Ltd. Shenzhen 518000, China. Electronic address: wangjinhui@hrbmu.edu.cn.

Abstract

Idiopathic Pulmonary fibrosis (IPF) is diagnosed as a life-threatening, progressive and incurable lung disease characterized by accumulation of extracellular matrix and myofibroblasts, resulting in the function degradation and structural alterations in normal lung parenchyma. Notably, Pulmonary Fibrosis has been considering as a difficult problem in clinical with high mortality and effective treatment strategies. Rosavin, a benzylPropylene glycoside, is isolated from Rhodiola rosea L., exhibiting nootropic, anti-depressant, anti-cancer, anti-inflammatory and anti-oxidative activities. In this study, we attended to elucidate the pharmacological activity of Rosavin for treatment of pulmonary fibrosis induced by bleomycin in mice. The results indicated that Rosavin could significantly ameliorate the lung index and Pathological structure of mice with Pulmonary fibrosis by bleomycin-induced. Additionally, Rosavin could evidently decreased inflammatory cells infiltration in bronchoalveolar lavage fluid and pro-inflammatory cytokines expression in lung tissue specimens induced by bleomycin. Rosavin could down-regulate the expression of hydroxyproline and malondialdehyde and increased the activities of superoxide dismutase, glutathione peroxidase in lung tissue. The expression of Nrf2 were increased, and the expression of NF-κB p65, TGF-β1 and α-SMA were inhibited. The findings revealed the protective effects and the primary mechanism of rosavin on bleomycin-induced pulmonary fibrosis, which provided a scientific foundation for Rosavin as a promising candidate for Pulmonary fibrosis treatment.

KEYWORDS:

Anti-oxidant; Bleomycin; Inflammatory response; Pulmonary fibrosis; Rosavin

PMID:
31026730
DOI:
10.1016/j.biopha.2019.108870
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center